The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans.
about
Application of an updated physiologically-based pharmacokinetic model for chloroform to evaluate CYP2E1-mediated renal toxicity in rats and miceThe metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroformThe use of in vitro data in risk assessment.Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments.Trichloroethylene biotransformation and its role in mutagenicity, carcinogenicity and target organ toxicity.Issues in the pharmacokinetics of trichloroethylene and its metabolites.Human health effects of dichloromethane: key findings and scientific issuesFramework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment.Approaches for applications of physiologically based pharmacokinetic models in risk assessment.Trichloroethylene risk assessment: a review and commentary.The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes.Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach.A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.The impact of variation in scaling factors on the estimation of internal dose metrics: a case study using bromodichloromethane (BDCM).Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough.In vitro metabolism of the fungicide and environmental contaminant trans-bromuconazole and implications for risk assessment.The Ontogeny of Cytochrome P450 Enzyme Activity and Protein Abundance in Conventional Pigs in Support of Preclinical Pediatric Drug Research.
P2860
Q23909643-0745011E-98EF-4B21-9FE5-FF366FDFD55EQ23915080-453C89F6-FC3E-4BF4-AA66-730C281BF8C4Q30983596-F763D6C2-A772-4EFC-AEE0-92BAF23D3DDEQ33519666-21C320DF-56B1-4BA8-9068-162EAF603095Q34626393-9993E168-C373-4EA2-961F-68862DB0687CQ35039326-C220C11F-8AB1-45EC-B369-4B2365DF2469Q35039376-75934E7C-C4C1-4F1F-B45B-55B65F351881Q36014859-1DBD12FE-3AF3-4B74-B88E-ED1CA8904C73Q37201545-CEFAF94C-5C7E-4978-BDCF-9D7B2B147E28Q37620349-939881A6-47D8-410F-BACB-75A65411BB3CQ37698404-00AF4B17-3F34-4ADD-8D3E-D8AB23642919Q38016204-7C0EC29C-FBEE-4015-87A0-AA7645A147ECQ44867941-E586EEE0-66C0-42AE-9E00-BDDCFE2C0F60Q47254105-060FC069-B314-49FD-B728-0B9FB5B054B5Q51533586-89634616-9C09-46DB-925A-312868BBB1B9Q53399970-40570B2B-7FE1-4CA3-A81B-C30FEB222E0CQ53546151-E4EBE655-1EF4-4986-882C-A0686577FBADQ54961613-E8CBE336-98C7-44D0-B4B7-B4281F9405D2
P2860
The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
The impact of cytochrome P450 ...... macokinetic outcome in humans.
@en
The impact of cytochrome P450 ...... macokinetic outcome in humans.
@nl
type
label
The impact of cytochrome P450 ...... macokinetic outcome in humans.
@en
The impact of cytochrome P450 ...... macokinetic outcome in humans.
@nl
prefLabel
The impact of cytochrome P450 ...... macokinetic outcome in humans.
@en
The impact of cytochrome P450 ...... macokinetic outcome in humans.
@nl
P2093
P2860
P1433
P1476
The impact of cytochrome P450 ...... macokinetic outcome in humans.
@en
P2093
Doug Popken
Gregory L Kedderis
Jeff Swartout
John C Lipscomb
Linda K Teuschler
P2860
P304
P356
10.1111/J.0272-4332.2003.00397.X
P577
2003-12-01T00:00:00Z